High KRAS expression levels were associated with overall survival (OS) in ACC, LUAD, PAAD and UCEC (Figure 2A); poor disease-specific survival (DSS) in ACC, LUAD and PAAD (Figure 2B); poor disease-free interval (DFI) in ACC, LUAD, PAAD and STAD (Figure 2C); and poor progression-free interval (PFI) in adrenocortical carcinoma (ACC), LUAD, PAAD, STAD and uveal melanoma (UVM) (Figure 2D). Here, KRAS is linked to uveal melanoma.